Astragalus Polysaccharide Promotes NLRP3+ Macrophages Polarization via Suppression of OGT in Hepatocellular Carcinoma
- Immunol Invest. 2026 May;55(4):750-773. doi: 10.1080/08820139.2026.2645964.
- 1. Department of Traditional Chinese Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
- 2. Department of Ultrasound Medicine, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Background: Hepatocellular carcinoma (HCC) is characterized by an immunosuppressive tumor microenvironment (TME) dominated by tumor-associated macrophages (TAMs). Astragalus polysaccharide (APS) exhibits anti-tumor activity, its mechanism in reprogramming immunosuppressive TAMs remains unclear.
Methods: We established a subcutaneous HCC tumor model in C57BL/6 mice and administered APS. Single-cell RNA Sequencing (scRNA-seq) was performed to profile immune cell landscapes in HCC TME. Flow cytometry, immunofluorescence, and functional assays were employed to explore the role of O-linked N-acetylglucosamine transferase (OGT) in APS-mediated TME reprogramming.
Results: APS significantly inhibited tumor growth and remodeled the TME cellular composition. ScRNA-seq revealed 10 cell types in HCC mice tumor tissue. APS increased neutrophils, macrophages, and mast cells while reducing Other immune populations. Macrophages were subclassified into C1QC+ TAM, NLRP3+ TAM, and S100A9+ TAM. APS specifically elevated NLRP3+ TAM abundance, which positively correlated with M1-like pro-inflammatory phenotypes (TNFα, complement pathway activation). Mechanistically, APS downregulated OGT expression and global O-GlcNAcylation in TAMs, promoting NLRP3+ TAM polarization. NLRP3+ TAMs with APS treatment secreted pro-inflammatory cytokines and chemokines (IL-6, IL-1B, TNFα, and CXCL10), enhancing CD8+ T-cell infiltration and reducing T-cell exhaustion.
Conclusion: APS suppresses HCC by inhibiting OGT-mediated O-GlcNAcylation and promoting NLRP3+ M1-like TAMs enrichment, thereby enhancing anti-tumor immunity, highlighting APS as a potential immunomodulatory agent for HCC therapy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: NOD-like Receptor (NLR)Research Areas: Inflammation/Immunology
-
Research Areas: Metabolic Disease